Take Homes in Lung Cancer

Take Homes in Lung Cancer

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics. Tsuboi reports receiving honoraria from AstraZeneca KK, Boehringer-Ingelheim Japan, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan, Johnson & Johnson Japan, Medtronic Japan, MSD, Ono Pharmaceutical Co., Ltd., Taiho Pharma and Teijin Pharma; and research grant/funding to institution from AstraZeneca KK, Boehringer-Ingelheim Japan and MSD.
November 12, 2020
1 min watch
Save

VIDEO: Treatment options in lung cancer ‘advancing faster than ever’

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics. Tsuboi reports receiving honoraria from AstraZeneca KK, Boehringer-Ingelheim Japan, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan, Johnson & Johnson Japan, Medtronic Japan, MSD, Ono Pharmaceutical Co., Ltd., Taiho Pharma and Teijin Pharma; and research grant/funding to institution from AstraZeneca KK, Boehringer-Ingelheim Japan and MSD.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, spoke with Healio about presentations from the Chemotherapy Foundation Symposium exploring liquid biopsy in lung cancer.

“We really had great discussion and excitement,” Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, said. “The treatment of lung cancer is advancing faster than ever before.”

References:

  • Aggarwal C. Leveraging Liquid Biopsies to Tailor Treatment Decisions. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.
  • Patel SP. Frontline Immunotherapy Strategies for Non-Oncogene-Driven, Advanced Lung Adenocarcinoma. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.